Wakamoto Pharmaceutical Co., Ltd. AI Stock Analysis
Want to see JP:4512 full AI Analyst Report?
Wakamoto Pharmaceutical Co., Ltd. (4512) AI Stock Analysis
Wakamoto Pharmaceutical Co., Ltd.
(TSE/TYO:4512)
Wakamoto Pharmaceutical scores poorly, driven primarily by persistently negative operating and free cash flow and very thin profitability, which raise concerns about earnings quality and the sustainability of the business model without external funding. A fortress-like, near debt-free balance sheet and a forecast 27.2% revenue rebound provide some cushion and a potential turnaround signal, but chronically low returns on equity show weak capital efficiency. Technicals add little support, with the shares trading below most key moving averages and a negative MACD. Valuation compounds the risk, as a P/E near 56 is difficult to justify on current earnings power, with only a 1.2% dividend yield as offset.
Wakamoto Pharmaceutical Co., Ltd. (4512) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 9.82B
- Dividend Yield
- 1.21%
- Average Volume (3M)
- 38.07K
- Price to Earnings (P/E)
- 54.1
- Beta (1Y)
- 0.40
- Revenue Growth
- 23.41%
- EPS Growth
- 149.71%
- Country
- Japan
- Employees
- 303
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Wakamoto Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Headquartered in Tokyo, Japan, Wakamoto Pharmaceutical Co., Ltd. specializes in the production and distribution of both prescription and over-the-counter pharmaceuticals across the country. Their diverse offerings include Strong Wakamoto, a widely re...
Wakamoto Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Financials are weak overall. Cash flow is the biggest problem (score 18): operating cash flow has been negative in three of the last four periods (-¥592M in FY2025, -¥487M forecast FY2026) and free cash flow is deeply negative near -¥1.05B, meaning reported profits are not backed by cash. The income statement (score 32) shows an encouraging 27.2% revenue rebound to ¥9.9B forecast for FY2026, but margins are razor-thin (2.3% net, 2.6% EBIT) after operating losses in three of five years and a ¥602M net loss in FY2021. The balance sheet (score 68) is the clear bright spot, with a near debt-free structure (debt/equity under 3.4%) and ~¥12B of equity providing downside protection — though chronically low ROE (-5.3% to 2.1%) shows that capital is poorly utilized.
Income Statement
32NegativeBalance Sheet
68PositiveCash Flow
18Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.98B | 9.91B | 7.79B | 7.74B | 8.66B | 8.38B |
| Gross Profit | 3.75B | 4.73B | 3.62B | 3.54B | 4.11B | 4.36B |
| EBITDA | 397.01M | 701.22M | 438.68M | 570.97M | 657.90M | 755.52M |
| Net Income | -177.67M | 227.22M | 64.44M | 108.96M | 138.26M | 238.54M |
Balance Sheet | ||||||
| Total Assets | 15.25B | 16.50B | 15.00B | 15.42B | 15.71B | 14.95B |
| Cash, Cash Equivalents and Short-Term Investments | 3.56B | 2.01B | 2.95B | 3.66B | 3.88B | 3.23B |
| Total Debt | 100.00M | 400.00M | 100.00M | 130.73M | 529.00K | 2.65M |
| Total Liabilities | 3.55B | 4.49B | 3.39B | 3.39B | 3.80B | 3.47B |
| Stockholders Equity | 11.70B | 12.01B | 11.61B | 12.03B | 11.91B | 11.48B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.05B | -1.04B | -663.02M | 420.76M | -28.97M |
| Operating Cash Flow | 0 | -486.91M | -592.45M | -107.34M | 631.92M | 339.17M |
| Investing Cash Flow | 0 | -657.56M | -13.50M | -2.35M | 17.13M | 50.57M |
| Financing Cash Flow | 0 | 195.88M | -103.94M | -104.99M | -1.61M | -1.62M |
Wakamoto Pharmaceutical Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4512, the sentiment is Negative. The current price of 289.00 is below the 20-day moving average (MA) of 293.35, below the 50-day MA of 296.26, and below the 200-day MA of 302.50, indicating a bearish trend. The MACD of -2.69 indicates Positive momentum. The RSI at 45.41 is Neutral, neither overbought nor oversold. The STOCH value of 78.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4512.
Wakamoto Pharmaceutical Co., Ltd. Peers Comparison
Overall Rating
JP:457469Neutral
JP:452468Neutral
JP:457767Neutral
JP:453863Neutral
JP:292957Neutral
JP:451239Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 69Neutral | JPY 12.72B | 29.84 | ― | 1.30% | 13.72% | -50.46% | |
| 68Neutral | JPY 8.99B | 10.27 | ― | 2.95% | -0.47% | 50.82% | |
| 67Neutral | JPY 37.71B | 11.98 | ― | 3.06% | -2.83% | 65.69% | |
| 63Neutral | JPY 19.04B | 8.28 | ― | 4.15% | 2.29% | ― | |
| 57Neutral | JPY 15.50B | 7.54 | ― | 4.67% | -3.12% | 406.78% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 39Underperform | JPY 10.03B | 54.14 | ― | 1.21% | 23.41% | 149.71% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4512 | Wakamoto Pharmaceutical Co., Ltd. | 289.00 | 15.31 | 5.59% | |
| JP:2929 | Pharma Foods International Co., Ltd. | 535.00 | -237.43 | -30.74% | |
| JP:4524 | Morishita Jintan Co., Ltd. | 2204.00 | 111.04 | 5.31% | |
| JP:4538 | Fuso Pharmaceutical Industries,Ltd. | 2170.00 | 60.42 | 2.86% | |
| JP:4574 | Taiko Pharmaceutical Co., Ltd. | 254.00 | -39.00 | -13.31% | |
| JP:4577 | Daito Pharmaceutical Co., Ltd. | 1307.00 | 77.98 | 6.34% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 19, 2026
